We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sanofi | EU:SAN | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.26 | -1.35% | 91.82 | 100.00 | 83.60 | 94.03 | 91.33 | 93.99 | 865,732 | 16:31:50 |
From May 2019 to May 2024
By Stephen Nakrosis
Lexicon Pharmaceuticals Inc. (LXRX) said Tuesday it had terminated an alliance with Sanofi to develop and commercialize Zynquista.
Zynquista, or sotagliflozin, has been approved in the European Union for use as an adjunct to insulin therapy in adults with type 1 diabetes. Besides that approval, Zynquista is investigational and hasn't been approved by any other regulatory authority for type 1 or type 2 diabetes, Lexicon said.
Lexicon said it will regain all rights to Zynquista and take responsibility for worldwide development and commercialization in both type 1 and type 2 diabetes.
Sanofi will pay Lexicon $260 million, of which $208 million is payable upfront. The remaining money is payable within 12 months, Lexicon said.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
September 10, 2019 16:39 ET (20:39 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
